Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.
2.

Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study.

Altamura AC, Buoli M, Albano A, Dell'Osso B.

Int Clin Psychopharmacol. 2010 May;25(3):172-9. doi: 10.1097/YIC.0b013e3283384c74.

PMID:
20305566
3.

Factors associated with the duration of untreated illness among patients with obsessive compulsive disorder.

Poyraz CA, Turan Ş, Sağlam NG, Batun GÇ, Yassa A, Duran A.

Compr Psychiatry. 2015 Apr;58:88-93. doi: 10.1016/j.comppsych.2014.12.019.

PMID:
25596625
4.

Differences in duration of untreated illness, duration, and severity of illness among clinical phenotypes of obsessive-compulsive disorder.

Dell'Osso B, Benatti B, Oldani L, Spagnolin G, Altamura AC.

CNS Spectr. 2015 Oct;20(5):474-8. doi: 10.1017/S1092852914000339.

PMID:
24967664
5.

Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder.

Dell'Osso B, Buoli M, Hollander E, Altamura AC.

World J Biol Psychiatry. 2010 Feb;11(1):59-65. doi: 10.3109/15622970903418544.

PMID:
20001657
6.

Obsessive-compulsive disorder and separation anxiety co-morbidity in early onset panic disorder.

Goodwin R, Lipsitz JD, Chapman TF, Mannuzza S, Fyer AJ.

Psychol Med. 2001 Oct;31(7):1307-10.

PMID:
11681556
7.

Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders.

Dell'Osso B, Cremaschi L, Palazzo C, Suardi N, Spagnolin G, Camuri G, Benatti B, Oldani L, Dobrea C, Arici C, Pace G, Tiseo A, Nahum ES, Castellano F, D'Urso N, Clerici M, Primavera D, Carpiniello B, Altamura AC.

Int Clin Psychopharmacol. 2015 Jan;30(1):29-35. doi: 10.1097/YIC.0000000000000049.

PMID:
25117878
8.

Duration of untreated illness and duration of illness in anxiety disorders: assessment and influence on outcome.

Altamura AC, Camuri G, Dell'Osso B.

Mod Trends Pharmacopsychiatri. 2013;29:111-8. doi: 10.1159/000351950. Review.

PMID:
25225021
9.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Review. French.

PMID:
18922243
11.

Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder.

Altamura AC, Dell'osso B, D'Urso N, Russo M, Fumagalli S, Mundo E.

CNS Spectr. 2008 May;13(5):415-22.

PMID:
18496479
12.

The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS).

Dell'Osso B, Benatti B, Buoli M, Altamura AC, Marazziti D, Hollander E, Fineberg N, Stein DJ, Pallanti S, Nicolini H, Van Ameringen M, Lochner C, Hranov G, Karamustafalioglu O, Hranov L, Menchon JM, Zohar J; ICOCS group..

Eur Neuropsychopharmacol. 2013 Aug;23(8):865-71. doi: 10.1016/j.euroneuro.2013.05.004.

PMID:
23791074
13.

DSM-III personality disorders in generalized anxiety, panic/agoraphobia, and obsessive-compulsive disorders.

Mavissakalian MR, Hamann MS, Abou Haidar S, de Groot CM.

Compr Psychiatry. 1993 Jul-Aug;34(4):243-8.

PMID:
8348802
14.

Prevalence of panic disorder and other subtypes of anxiety disorder and their background.

Takahashi S, Nakamura M, Iida H, Iritani S, Fujii M, Yamashita Y, Yoichi I.

Jpn J Psychiatry Neurol. 1987 Mar;41(1):9-18.

PMID:
3498072
15.

The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders.

Lee JH, Dunner DL.

Depress Anxiety. 2008;25(2):91-7.

PMID:
17311265
16.

The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.

Shavitt RG, Valério C, Fossaluza V, da Silva EM, Cordeiro Q, Diniz JB, Belotto-Silva C, Cordioli AV, Mari J, Miguel EC.

Eur Arch Psychiatry Clin Neurosci. 2010 Mar;260(2):91-9. doi: 10.1007/s00406-009-0015-3.

PMID:
20077119
17.

Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?

Benatti B, Camuri G, Dell'Osso B, Cremaschi L, Sembira E, Palazzo C, Oldani L, Dobrea C, Arici C, Primavera D, Carpiniello B, Castellano F, Carrà G, Clerici M, Baldwin DS, Altamura AC.

Int Clin Psychopharmacol. 2016 Nov;31(6):347-52. doi: 10.1097/YIC.0000000000000137.

PMID:
27384739
18.

[Early signs and symptoms before the psychotic onset. A study on the Duration of Untreated Illness (DUI) in a sample of patients with diagnosis of "non-affective psychotic disorders"].

Bensi M, Armando M, Censi V, Aiello D, Fortes Lindau J, Cavaggioni G, Birchwood M, Fiori Nastro P.

Clin Ter. 2011;162(1):11-8. Italian.

PMID:
21448540
19.

Remission rates in patients with anxiety disorders treated with paroxetine.

Ballenger JC.

J Clin Psychiatry. 2004 Dec;65(12):1696-707.

PMID:
15641876
20.

The generalized anxiety spectrum: prevalence, onset, course and outcome.

Angst J, Gamma A, Baldwin DS, Ajdacic-Gross V, Rössler W.

Eur Arch Psychiatry Clin Neurosci. 2009 Feb;259(1):37-45. doi: 10.1007/s00406-008-0832-9.

PMID:
18575915

Supplemental Content

Support Center